# Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab.

*biotech · news · 2026-04-13 · MarketScreener*

## Key points

- The BRUIN CLL-322 trial showed pirtobrutinib plus venetoclax and rituximab improved progression-free survival.
- Improvement in progression-free survival was consistent regardless of prior covalent BTK inhibitor treatment.
- Overall survival data are not mature but currently trend in favor of the pirtobrutinib combination.
- Safety profiles and discontinuation rates were similar between the pirtobrutinib combination and control arms.
- Lilly plans to submit these results for regulatory label expansion later this year.

**Companies:** Eli Lilly and Company

[Read the full story on MarketScreener](https://www.marketscreener.com/news/eli-lilly-and-company-announces-positive-phase-3-results-for-jaypirca-pirtobrutinib-in-previously-ce7e50dedc8df225)

---

Canonical: https://newsio.io/n/6798162a-a65c-4c0b-9c63-03d4aa5d7081/jaypirca-pirtobrutinib-a-non-covalent-reversible-bruton-tyrosine-kinase-btk-inhi
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works